Clinical Trial

Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)

Study acronym: SPRINT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2023 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Intervention prospective monocentric one arm study on the use of neoadjuvant radiotherapy with simultaneous integrated boost (Simultaneous Integrated Boost, SIB) in patients with STS with indication for preoperative radiotherapy. The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy / fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed.
Trial Details
NCT Number NCT05761054
Lead Sponsor Azienda Ospedaliero-Universitaria Careggi
Conditions Soft Tissue Sarcoma
Enrollment 33 participants
Start Date 2022-07-19
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2023-03-09